This mechanism is central to the pathophysiology of hypercholesterolemia and related cardiovascular diseases, as gain-of-function mutations in PCSK9 can lead to familial hypercholesterolemia, whereas loss-of-function mutations are associated with hypocholesterolemia [34, 35]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.